Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

References

• Franks HA, Wang Q, Patel PM. New anticancer immunotherapies. Anticancer Res 2012 Jul; 32(7):2439-53; PMID:22753700
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011 Jul; 73(1):11-7 Epub 2011 Apr 6. Review; PMID:21474197; http://dx.doi.org/10.1016/j.lungcan.2011.02.023
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011 Jan; 18(1):23-34 Epub 2010 Nov 3. Review; PMID:21048000; PMID:24316553; http://dx.doi.org/10.1128/CVI.00286-10
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009; 46(4):167-89 Review; PMID:19650714; http://dx.doi.org/10.1080/10408360902937809
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16(36):4779-96 Review; PMID:19929787; http://dx.doi.org/10.2174/092986709789909648
   PubMed Web of Science ®Google Scholar
• Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Faure O, Graf-Dubois S, Marrocco J, Chouaib S et al. A polyepitope DNA vaccine targeted to HER2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 2007 Jul 15; 67(14):7028-36; PMID:17638916; http://dx.doi.org/10.1158/0008-5472.CAN-06-3998
   PubMed Web of Science ®Google Scholar
• Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P et al. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 2002 Nov 1; 169(9):4840-9; PMID:12391194; http://dx.doi.org/10.4049/jimmunol.169.9.4840
   PubMed Web of Science ®Google Scholar
• Correale P, Sabatino M, Cusi MG, Micheli L, Nencini C, Pozzessere D, Petrioli R, Aquino A, De Vecchis L, Turriziani M et al. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother 2001 Oct; 13(5):519-26; PMID:11760216; http://dx.doi.org/10.1179/joc.2001.13.5.519
   PubMed Web of Science ®Google Scholar
• Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A et al. Five-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 2005 Oct 5; 97(19):1437-45; PMID:16204693; http://dx.doi.org/10.1093/jnci/dji188
   PubMedGoogle Scholar
• Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci 2004 Sep 1; 9:2467-73. Review; PMID:15353299; http://dx.doi.org/10.2741/1408
   PubMed Web of Science ®Google Scholar
• Van Der Wilt CL, Peters GJ. New targets for pyrimidine antimetabolites in the treatment of solid tumours. One: Thymidylate synthase. Pharm World Sci 1994 Apr 15; 16(2):84-103; PMID:7518280; http://dx.doi.org/10.1007/BF01880660
   PubMedGoogle Scholar
• Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PLoS One 2012; 7(10):e47318. Epub 2012 Oct 9; PMID:23056627; http://dx.doi.org/10.1371/journal.pone.0047318
   PubMedGoogle Scholar
• Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Gori Savellini G, Terrosi C, Mannucci S, Giorgi G, Francini G et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide specific CTLs. J Immunother 2008; 31:132-47; PMID:18481383; http://dx.doi.org/10.1097/CJI.0b013e31815b69c8
   PubMed Web of Science ®Google Scholar
• Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 2005 Jul 15; 175(2):820-8; PMID:16002679; http://dx.doi.org/10.4049/jimmunol.175.2.820
   PubMed Web of Science ®Google Scholar
• Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005 Dec 10; 23(35):8950-8. Epub 2005 Aug 1; PMID:16061910; http://dx.doi.org/10.1200/JCO.2005.12.147
   PubMed Web of Science ®Google Scholar
• Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, De Vecchis L et al. Treatment of colon and breast carcinoma cells with 5-Fluorouracil enhances expression of carcinoembryonic antigen and to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003 Apr 10; 104(4):437-45; PMID:12584740; http://dx.doi.org/10.1002/ijc.10969
   PubMed Web of Science ®Google Scholar
• Correale P, Marra M, Remondo C, Migali C, Arcuri FP, Carducci A, Loiacono L, Abruzzese A, Tagliaferri P, Caraglia M. Cytotoxic drugs up-regulate Epidermal Growth Factor Receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted Antibody-Dependent-Cell-mediated-Cytotoxicity (ADCC). Eur J Cancer Jun 2010; 46(9):1703-11, IF= 4.454; PMID:20399639; http://dx.doi.org/10.1016/j.ejca.2010.03.005
   PubMed Web of Science ®Google Scholar
• Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi M, Gori Savellini G, Bestoso E, Apollinari S, Ginanneschi C, Mannucci S et al. Cetuximab −/− chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2012 Apr 1; 130(7):1577-89 Epub 2011 Aug 16; PMID:21618510; http://dx.doi.org/10.1002/ijc.26181
   PubMed Web of Science ®Google Scholar
• Botta C, Correale P. Cetuximab-based immune-chemotherapy enhances antigen presentation and cytotoxic T cell activity in colorectal cancer patients. J Immunotherapy 2012 Jun; 35(5):440-7; PMID:22576349; http://dx.doi.org/10.1097/CJI.0b013e31825943aa
   PubMed Web of Science ®Google Scholar
• Correale P, TagliaferriP, Fioravanti A, Del VecchioMT, RemondoC, Montagnani F, RotundoMS, Ginanneschi C, Martellucci I, Francini E et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemo-immunotherapy with Gemcitabine + FOLFOX followed by subcutaneous Granulocyte Macrophage-Colony Stimulating Factor and Aldesleukine (GOLFIG-1 trial). Clin Cancer Res 2008; 14(13):4192-9; PMID:18593999; http://dx.doi.org/10.1158/1078-0432.CCR-07-5278
   PubMed Web of Science ®Google Scholar
• Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG et al. Immune-boost with gemcitabine, oxaliplatin, levofolinate, 5-flurouracil, granulocyte/macrophage colony-stimulating-factor (GM-CSF) and aldesleukine (GOLFIG) enhances progression-free and overall-survival over FOLFOX chemotherapy in metastatic colorectal cancer patients: GOLFIG-2 multi-centric open label randomized phase III trial. J Immunother 2014 Jan; 37(1):26-35; PMID:24316553; http://dx.doi.org/10.1097/CJI.0000000000000004
   PubMed Web of Science ®Google Scholar
• Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol Immunother. 2015 Sep; 64(9):1159-73; PMID:26031574; http://dx.doi.org/10.1007/s00262-015-1711-7.
   Google Scholar
• CorrealeP, Campoccia G, Tsang KY, Micheli L, CusiG, Sabatino M, BruniG, SestiniS, PetrioliR, Pozzessere D et al. Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hr IL-2: results from a Phase Ib Clinical Trial. Eur J Cancer 2001; 37 (7):892-902; PMID:11313178; http://dx.doi.org/10.1016/S0959-8049(01)00063-6
   PubMed Web of Science ®Google Scholar
• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Met 1983; 65 (1-2):109-21; PMID:6361139; http://dx.doi.org/10.1016/0022-1759(83)90308-3
   PubMed Web of Science ®Google Scholar
• Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59 (10):1489-501; PMID:20549207; http://dx.doi.org/10.1007/s00262-010-0875-4
   PubMed Web of Science ®Google Scholar
• Correale P, Bertoldi I, Miracco C, FioravantiA, Francini G. Occurrence of discoid lupus erythematousus in a good responder colon carcinoma patient receiving chemo-immunotherapy. J Chemother. 2008 Apr; 20(2):278-81. IF= 0.922; PMID:18467257; http://dx.doi.org/10.1179/joc.2008.20.2.278
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454 (7203):436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci USA 2013; 110 (5):E415-424; PMID:23271806; http://dx.doi.org/10.1073/pnas.1211850110
   PubMedGoogle Scholar
• Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol therapy 2013; 14 (6):469-75; PMID:23760488; http://dx.doi.org/10.4161/cbt.24425
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC cancer 2013; 13:158; PMID:23530866; http://dx.doi.org/10.1186/1471-2407-13-158
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106 (6):dju124; PMID:24875653; http://dx.doi.org/10.1093/jnci/dju124
   PubMedGoogle Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133 (5):775-87; PMID:18510923; http://dx.doi.org/10.1016/j.cell.2008.05.009
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 2009; 39 (8):2076-82; PMID:19672903; http://dx.doi.org/10.1002/eji.200939722
   PubMed Web of Science ®Google Scholar
• Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99 (1):23-33; PMID:10520991; http://dx.doi.org/10.1016/S0092-8674(00)80059-8
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-63; PMID:15032595; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012; 18 (3):850-7; PMID:22142823; http://dx.doi.org/10.1158/1078-0432.CCR-10-3186
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunol 2012; 1 (4):531-2; PMID:22754775; http://dx.doi.org/10.4161/onci.19404
   PubMed Web of Science ®Google Scholar
• Terrazzano G, Carbone E. NK cells blur the frontier between innate and acquired immunity. Front Immunol 2012; 3:400; PMID:23293641; http://dx.doi.org/10.3389/fimmu.2012.00400
   PubMed Web of Science ®Google Scholar